20-F: PRF Technologies Shifts Focus After Clinical Setback, Eyes AI Solar Growth

PRF Technologies reports significant losses and a going concern warning, pivoting its drug development to OcuRing-K while expanding its DeepSolar AI analytics business.

Summary

• PRF Technologies Ltd. (formerly PainReform Ltd.) is a diversified technology innovation company focusing on specialty pharmaceutical therapies and AI-driven energy analytics.
• The company reported a net loss of $4.8 million for the year ended December 31, 2025, a significant improvement from $14.6 million in 2024 and $9.3 million in 2023.
• Operating cash outflows were negative $4.0 million in 2025, compared to negative $12.6 million in 2024 and negative $6.7 million in 2023.
• As of December 31, 2025, the company had an accumulated deficit of $61.3 million and cash and cash equivalents of $4.1 million.
• The independent registered public accounting firm included a going concern explanatory paragraph due to recurring losses and negative cash flows, indicating substantial doubt about the company's ability to continue operations for at least the next 12 months.
• The Phase 3 clinical trial for PRF-110, a post-surgical pain management candidate, did not satisfy its primary endpoint in December 2024, leading to a substantial scale-back of R&D activities for this product.
• In August 2025, the company acquired a controlling interest in LayerBio Inc., a biotechnology company focused on ophthalmic drug delivery, making OcuRing-K its new primary clinical focus.
• OcuRing-K is an intraoperatively administered sustained-release ocular therapy for post-cataract surgery pain and inflammation, with preclinical and Phase 1 studies showing a favorable safety profile.
• In March 2025, the company acquired the DeepSolar AI-driven solar analytics technology from BladeRanger Ltd., marking an entry into the renewable energy sector.
• DeepSolar's technology optimizes solar energy assets, offering real-time monitoring, performance analytics, and automated maintenance solutions for utility-scale and residential users.
• The company initiated a strategic pilot program for DeepSolar with Econergy Renewable Energy Ltd. at a 92-megawatt plant in Romania in May 2025.
• DeepSolar was accepted into the NVIDIA Connect Program in August 2025 and launched Smart TDD (Technical Due Diligence) service in January 2026.
• Multiple reverse share splits were effected: 1-for-10 in June 2023, 1-for-6 in September 2024, 1-for-4 in November 2024, and 1-for-5 in February 2026.
• A material weakness in internal control over financial reporting was identified for the year ended December 31, 2025, due to insufficient finance staff and incomplete segregation of duties.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for PRF Technologies, marked by a major clinical trial failure and ongoing financial instability, despite strategic acquisitions and early progress in new business segments.

Positives

• Net loss significantly decreased to $4.8 million in 2025 from $14.6 million in 2024, primarily due to reduced clinical trial costs for PRF-110.
• Strategic acquisition of LayerBio Inc. in August 2025 diversifies the pharmaceutical pipeline with OcuRing-K, a promising sustained-release ocular therapy.
• Preclinical and Phase 1 clinical studies for OcuRing-K demonstrated a favorable safety profile, supporting its advancement to later-stage development.
• Entry into the AI-driven solar analytics market with the acquisition of DeepSolar technology in March 2025 provides a new growth vertical.
• DeepSolar launched a strategic pilot program with Econergy Renewable Energy Ltd. in Romania, indicating early commercial traction.
• DeepSolar's acceptance into the NVIDIA Connect Program and the launch of Smart TDD service enhance its market position and product offerings.
• Financial income increased to $108,000 in 2025 from $93,000 in 2024, mainly due to higher average deposit balances.

Negatives

• The company has incurred significant losses and negative cash flows from operations since inception, with an accumulated deficit of $61.3 million as of December 31, 2025.
• The independent auditor's report includes a going concern explanatory paragraph, highlighting substantial doubt about the company's ability to continue operations.
• The Phase 3 clinical trial for PRF-110 failed to meet its primary endpoint in December 2024, leading to a substantial scale-back of R&D activities for this product.
• Multiple reverse share splits (1-for-10, 1-for-6, 1-for-4, 1-for-5) have been effected, which often indicate challenges in maintaining stock price and Nasdaq listing requirements.
• A material weakness in internal control over financial reporting was identified due to insufficient finance staff and incomplete segregation of duties, impacting financial reporting reliability.
• The company will need substantial additional funding to continue operations and advance product candidates, with no committed external source of funds currently available.

Risks

• Ability to continue as a going concern due to history of losses and need for additional capital.
• Dependence on the success of product candidates (OcuRing-K and DeepSolar solution) and ability to obtain regulatory approval and commercialize them.
• Limited experience in conducting and managing large-scale clinical trials.
• Reliance on third parties for clinical trials, product manufacturing, and development.
• Intense competition and new technologies in both biopharmaceutical and solar energy markets.
• Ability to comply with regulatory requirements for product development and marketing.
• Ability to establish and maintain strategic partnerships and corporate collaborations.
• Maintaining intellectual property rights and operating without infringing on others' IP.
• Impact of the political and security situation in Israel on operations.
• Risk of IT system failures, cybersecurity attacks, and data breaches.
• Failure to maintain compliance with Nasdaq minimum listing requirements, potentially leading to delisting.
• Limited shareholder protections due to foreign private issuer status and adherence to home country corporate governance practices.
• Material weakness in internal control over financial reporting could impair timely and accurate financial statements.
• Future issuance of ordinary shares may cause dilution to existing shareholders.
• Market price volatility of ordinary shares due to various factors, including clinical trial results and economic conditions.
• Uncertainty in the market for AI-based software applications and potential regulatory scrutiny over AI technologies.
• Challenges in scaling business operations and managing future growth of the DeepSolar business effectively.
• Loss of key members of the DeepSolar team could significantly disrupt the business.
• Obligations to the Israel Innovation Authority (IIA) for past grants, including royalty payments and restrictions on technology transfer.
• Dependence on widespread adoption of solar energy technologies and sufficient demand for software-enabled services.
• Inaccurate estimates of total addressable market for DeepSolar could negatively affect future growth.
• Product liability risks from clinical trials and commercial sales, with potential for inadequate insurance coverage.
• Currency exchange rate fluctuations and inflation affecting results of operations, particularly with NIS expenses.

Future Outlook

The company expects to continue incurring losses and negative cash flows until its product candidates (OcuRing-K, PRF-110) and the DeepSolar solution reach commercial profitability. Management plans to raise additional capital through equity offerings, debt financings, or strategic partnerships. The DeepSolar business aims to expand its footprint across solar plant portfolios and develop a wider portfolio of solutions, including enhancing its automated reporting engine and Smart TDD service. For OcuRing-K, the plan is to advance to Phase II clinical trials and build on the platform technology to broaden the product base in ophthalmology.

Management Comments

• "Our strategy is to incorporate generic drugs with our proprietary extended-release drug-delivery system in order to create extended-release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the FDA."
• "We believe that there is a great unmet need for effective, long-lasting, non-opiate treatments for post-operative pain."
• "We believe that patients deserve safe, effective, lasting treatments that are cost effective. We view intra-operational local application of drugs as resulting in lower drug loads, a better safety profile and the resolution of compliance issues endangering postsurgical recovery."
• "Our commitment to research and innovation is best witnessed by the fact that we developed both our proprietary platform technology and PRF-110 in-house, without in-licensing."
• "The DeepSolar technology enhances the profitability of solar assets by reducing operational costs, maximizing energy yield, and providing predictive analytics to drive better decision-making."
• "We recognize that to remain competitive, we must continuously invest in research and development, enhance our technological capabilities, and adapt to changing market conditions."

Industry Context

StockSavvy.ai notes PRF Technologies' strategic pivot reflects broader trends in the biopharmaceutical industry towards de-risked drug development pathways (505(b)(2)) and addressing unmet needs like non-opiate pain management and patient compliance in chronic conditions. The shift from PRF-110 to OcuRing-K aligns with the growing demand for sustained-release therapies in ophthalmology, a market seeing increased innovation to overcome traditional eye-drop limitations. The company's entry into AI-driven solar analytics with DeepSolar positions it in a rapidly expanding renewable energy market, where optimization software is crucial for maximizing efficiency and profitability. This diversification strategy, while introducing new risks, taps into two high-growth sectors, potentially mitigating reliance on a single, high-risk drug candidate.

Comparison to Industry Standards

• In post-operative pain management, PRF-110 aimed to compete with established extended-release products like Exparel (Pacira Pharmaceuticals, Inc., with $575 million revenues in 2024) and Zynrelef (Heron Therapeutics Inc., with $25.5 million revenues in 2024). The failure of PRF-110's Phase 3 trial indicates it did not meet the efficacy benchmarks set by these competitors.
• For OcuRing-K, the company expects to compete with retinal imaging device providers like Optomed, biopharmaceutical ophthalmic therapeutic developers like PanOptica and Lenz Therapeutics, and intraocular lens providers like Rayner. OcuRing-K's 'drop-less' approach aims to address compliance issues and inconsistent drug delivery, which are common drawbacks of traditional post-operative eye-drop regimens in the cataract surgery market (estimated 4 million surgeries annually in the US, 20-30 million globally).
• In the AI solar analytics market, DeepSolar competes with companies such as Power Factors, Green Project Management, and Meteocontrol. DeepSolar differentiates itself by offering AI analytics, seamless integration with all SCADA providers, an insights-based report generator, and a single software portal for all renewable energy sources, which the company believes provides a significant value add compared to competitors often focused on specific market segments or offering fewer integrated features.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not a party to any material legal or administrative proceedings.
• Not aware of any pending or threatened material legal or administrative proceedings against the company.

Related Party Transactions

• Acquisition of DeepSolar technology from BladeRanger Ltd. in March 2025, resulting in BladeRanger becoming a more than 5% beneficial owner of ordinary shares.
• Agreement with BladeRanger Ltd. on March 16, 2026, for identifying potential business prospects for DeepSolar, with potential warrant issuance as consideration.
• Indemnification agreements with current directors and executive officers, exculpating them from duty of care breaches and indemnifying them to the fullest extent permitted by Israeli law.
• Employment or services agreements with senior management, including Eyal Broder and Dr. Sigal Aviel, with standard provisions for non-solicitation, confidentiality, non-competition, and invention assignment.
• Granting of options to purchase ordinary shares to certain officers and directors as part of compensation.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from future capital raises and past reverse stock splits. Investment value is highly dependent on the success of early-stage product candidates and the DeepSolar business. The 'going concern' warning indicates substantial risk to investment.
• **Employees**: Retention of key personnel is critical for both drug development and DeepSolar. The company's ability to attract and retain skilled employees is vital for future success.
• **Customers (DeepSolar)**: Potential for enhanced efficiency and profitability of solar assets through AI analytics. Early pilot programs with partners like Econergy indicate potential for broader adoption.
• **Patients (OcuRing-K)**: Potential for improved post-surgical pain and inflammation control with a sustained-release, 'drop-less' ocular therapy, addressing compliance issues and side effects of traditional treatments.
• **Creditors**: The 'going concern' warning indicates increased risk for creditors, as the company's ability to meet financial obligations is uncertain without additional funding.

Next Steps

• Initiate Phase II clinical trial for OcuRing-K.
• Continue development of the DeepSolar technology to expand its portfolio of solutions.
• Establish a sales, marketing, and technical support infrastructure for the DeepSolar solution.
• Actively explore various financing and strategic alternatives to address the going concern uncertainty.
• Hire additional accounting and finance personnel or provide necessary training to remediate the material weakness in internal control over financial reporting.
• BladeRanger Ltd. will identify and introduce potential business prospects for collaboration with DeepSolar, with potential warrant issuance upon successful agreements.

Key Dates

Recommendation

The company faces severe financial challenges, evidenced by recurring losses, negative cash flows, and an explicit 'going concern' warning from its auditors. The failure of the Phase 3 clinical trial for PRF-110, previously a primary drug candidate, is a major setback. While the company has made strategic acquisitions in OcuRing-K and DeepSolar, these are early-stage ventures with uncertain commercialization timelines and profitability. The history of multiple reverse stock splits further signals underlying issues with maintaining market value and Nasdaq listing. The identified material weakness in internal controls adds to operational risk. Given the high financial risk, significant uncertainty in product development, and the need for substantial future capital, a seasoned investor would likely view this as a 'strong sell' due to the elevated risk of capital loss.

Keywords

Biotechnology, AI Analytics, Solar Energy, Drug Delivery, OcuRing-K, DeepSolar, Post-operative Pain, Ophthalmology, Clinical Trials, SEC Filing, Nasdaq, Israel, Pharmaceuticals, Renewable Energy, Corporate Governance